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High dose chemotherapy followed by autologous 
blood stem cell transplantation (ASCT) is standard treat­
ment for younger patients with symptomatic multiple 
myeloma (MM). The lymphocytes in the microenviron­
ment of MM cells are an essential part of the patho­
physiology of this incurable disease [1]. It has been 
previously shown that lymphocytes within the graft are 
linked to the survival of MM patients [2]. However, only 
little is known which lymphocyte subsets are responsible 
for this tumor protective effect. In the presented study 
we have analyzed the lymphocytes by immunopheno­
typing in the peripheral blood (PB) and in the apheresis 
product (AP) of 41 consecutive patients.
METHODS
Patients. 41 consecutive patients with multip­
le mye loma received ASCT between 11/1995 and 
07/2000. The study was approved by the Ethical 
committee of the University Munich and informed 
consent was obtained from each patient. Mobiliza­
tion chemotherapy and G­SCF was administered ac­
cording to the IEV regimen [3]. Peripheral blood stem 
cells were harvested when the post­nadir absolute 
leukocyte count rose above 5000/µl using a Cobe 
Spectra (Cobe, Heimstetten, Germany) or an AS104 
(Fresenius, St. Wendel, Germany) cell separator and 
standard programs. The harvested blood stem cells 
were mixed with an equal volume of a freezing solution 
which was prepared with 5% HSA and 100% DMSO 
(Cryoserv, Tera Pharmaceuticals, Midvale, Utah, USA) 
(4 : 1). Relapse was defined according to the EBMT 
criteria [4]. 
Flow cytometry. Cells in the AP and cells in the PB 
at the day of apheresis were analyzed. Immunopheno­
typing was performed with a three­color­fluorescence 
using an EPICS XL­MCL flow cytometer and the Sys­
tem II software (Beckman Coulter, Krefeld, Germany). 
100 µL of sample were incubated 15 min with saturating 
concentrations of the fluorochrome­conjungated an­
tibodies [5]. IgG1­FITC, IgG1­PE, CD45­FITC, CD3­
FITC, CD38­FITC, CD14­PE, CD19­PE, CD4­PE, CD8­
PE, CD56/CD16­PE, HLA­DR­PE, and CD138­PR were 
purchased from Immunotech (Marseille, France). 
Statistics. SPSS 11.5 for Microsoft Windows 
(SPSS Inc., Chicago, USA) was used for statistical 
analysis. The median number of positive cells was 
calculated for each marker and patients were assigned 
to a group either above or below median. To compare 
survival curves a log­rank test was performed and 
P < 0.05 was considered statistically significant.
RESULTS
Patients and stem cell harvest. The mean age 
was 56 years (range: 38–68) and 25 of the 41 patients 
were male (61%). Within the median follow up of 
3.9 years 30 pts experienced relapse (73%) and 13 pts 
died (32%). The median event free survival (EFS) was 
858 days (range: 104–2141 days), the median overall 
survival (OS) was 1406 days (range: 104–2557 days). 
Immunophenotyping of AP lymphocytes. 
A median of 78,000 leukocytes per µl (range: 12,000–
370,000/µl) was counted in the APs. 29% (7–63%) 
were lymphocytes. The table shows the lymphocyte 
pattern within the AP among the 41 tested patients. The 
composition of lymphocyte subsets expectantly refers 
rather well to values of the peripheral blood with 81% T­
cells (CD3), 1% B­cells, and 4% NK­cells (CD56/16). 
A small but still significant MM cell contamination was 
seen. The median CD4/CD8­ratio was 1.6 (range 0.2–
7.0) and 5% of lymphocytes expressed the activation 
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marker HLA­DR. With respect to the clinical outcome 
analysis below the displayed median values were used 
for discrimination between high and low. 
Table. Lymphocyte subsets within the peripheral blood stem cell grafts. After 
IEV mobilization treatment and GCSF stimulation leukapheresis was performed 
and lymphocyte subsets in the apheresis products of 41 consecutive multiple 
myeloma patients were determined by flow cytometry as indicated. Median 
and range are shown [% lymphocytes]. The median was used as cut off to 
discriminate between high and low for further data analysis
Lymphocyte Subsets Median Range
CD3 81 7–63
CD19 1 0–15
CD4 45 14–76
CD8 29 11–63
CD56/16 4 1–19
HLA-DR 5 1–37
CD138/CD38 0.03 0.00–0.84
Survival according to lymphocyte subsets with-
in the graft. First, it was tested whether plasma cells 
within the AP predict poor outcome. Figure a shows 
that the median EFS was not significantly diffe rent in 
patients with many plasma cells (CD138+CD38+ above 
median) in the AP (1268 ± 258 vs 1066 ± 140 days). 
This is in accordance to the results from PB. However, 
the percentage of B cells (CD19+) within the AP had 
a strong trend towards prediction of poor outcome 
(P = 0.051, see Figure a). 
Figure. Correlation of lymphocyte subsets within the peripheral 
blood stem cell graft with clinical outcome (EFS event free sur­
vival, OS overall survival) after high dose melphalan treatment. 
Patients were grouped according to the amount of specific 
lymphocyte subsets [% lymphocytes] within the stem cell graft 
(high versus low defined as above or below median respectively). 
EFS and OS were determined for the different groups and are 
shown as Kaplan — Meier blots. a, EFS depending on B cells 
(CD19) and plasma cells (CD138/CD38). b, EFS depending 
on CD4 cells and CD4/CD8 ratio. c, EFS and OS depending on 
HLA­DR positive cells
High leukocyte counts in the AP resulted in appa­
rently longer EFS (1363 ± 164 vs 862 ± 111 days) and 
slightly increased OS (1902 ± 138 vs 1663 ± 196 days), 
although these results did not reach statistical signifi­
cance (P = 0.074 and 0.288, respectively). 
A high percentage of CD4 cells was associated with 
a statistically significant prolongation of EFS (2179 ± 
170 vs 1670 ± 212 days; P = 0.003), which was ad­
ditionally reflected by the results obtained regarding 
OS (Figure b). A low proportion of CD8 cells and con­
sequently an increased T4/T8 ratio were significantly 
associated with good EFS (see Figure b). In addition, 
a small amount of activated lymphocytes (HLA­DR+) 
almost doubled EFS: 1370 ± 173 vs 751 ± 104 days 
(Figure c). This was also associated with a significantly 
prolonged OS (P = 0.020). 
Finally, none of the lymphocyte subsets in the pe­
ripheral blood at the day of aphaeresis correlated with 
any outcome parameter (OS, EFS). 
DISCUSSION
The study was conducted between 1995 and 2000. 
In the meantime several new drugs and treatment 
regimens for relapsed patients have been developed. 
Since probably all patients received these kind of 
effective salvage treatment OS is most likely a poor 
parameter to assess the influence of AP lymphocytes 
on outcome. It seems reasonable to focus on EFS in 
the discussion of the results. 
There is a trend towards a better prognosis with 
high leukocyte counts in the AP. This may be due to a 
more pronounced G­SCF responsiveness as an indica­
tor for the quality of the bone marrow microenviron­
ment [6]. However, peripheral blood leukocyte counts 
on the day of apheresis did not predict for EFS (data not 
shown). It has been shown previously that the absolute 
number of infused lymphocytes during ASCT predicts 
OS and time to progression in myeloma patients [2]. In 
our study the relative numbers of lymphocytes (CD3+ 
and CD19+) were associated with a trend towards a 
worse outcome, but this was due to the high num­
bers of granulocytes that reflect good bone marrow 
response to G­CSF. The relative amount of CD4 cells 
was associated with prolonged EFS in our study. The 
EFS was the same as the relapse free survival. The 
positive effect was therefore not due to prevention of 
infectious complications but improved tumor control. 
To the current knowledge more likely CD4 helper cells 
than cytotoxic T cells are capable of tumor surveillance 
and control [7–9]. Interestingly the most prominent 
association was found in our study with respect to 
activated lymphocytes (HLA­DR+). Two similar studies 
did not reveal significant relations [10–11]. However in 
the first peripheral blood was examined and in the latter 
allogeneic transplantations were performed, making 
both studies only poorly comparable. In the context 
with the above mentioned results regarding CD4 cells 
the negative impact of the activation marker HLA­DR 
may be explained by the fact that activated T cells are 
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more differentiated and less potent to transfer regula­
tory immune functions.
The number of plasma cells and as well the number 
of B cells in the AP do not determine the clinical out­
come of MM patients. This is in accordance with the 
failure of purging strategies [12] and supports the hy­
pothesis that the number of high dose chemotherapy 
surviving cells within in the body are quite higher than 
the number of plasma cells reinfused while ASCT. In 
contrast, the relative B cell amount in the graft was as­
sociated with an almost significant worsening of EFS. 
This corresponds well to the results of B cell purging 
in MM [13] and supports the hypothesis of precursor 
B cells as origin of relapse [14–15]. However, clonali­
ty was not assessed in the presented study and the 
sample size were probably too small to reach statistical 
significance. Further studies are needed to address 
this topic. 
Of note, a similar analysis was performed on 
lymphocytes in the PB at the day of leukapheresis, 
but none of the immunophenotyping parameters 
correlated with the outcome of the patients (data not 
shown). Most probably the high­dose chemotherapy 
diminishes the pre­existing immune function. More 
importantly, the lymphocytes within the graft signifi­
cantly influence the immune function after ASCT and 
herewith contribute to disease control [10, 16]. Indeed 
it has been supposed that the lymphocytes within the 
bone marrow influence the course of disease [17].
In summary, we suggest that a relative high pro­
portion of non­activated T helper cells within the 
graft predicts proper tumor control in MM patients 
after high­dose chemotherapy. Targeted lymphocyte 
preparation in the AP may further improve the results 
of ASCT in MM. 
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Т-ХЕЛПЕРЫ (CD3+/CD4+) АУТОЛОГИЧЕСКОГО 
ТРАНСПЛАНТАТА СТВОЛОВЫХ КЛЕТОК КРОВИ КОРРЕЛИРУЮТ 
С БЕЗРЕЦИДИВНОЙ ВЫЖИВАЕМОСТЬЮ БОЛЬНЫХ 
C МНОЖЕСТВЕННОЙ МИЕЛОМОЙ 
Микроокружение в костном мозге, включая лимфоциты, оказывает влияние на патофизиологию множественной миеломы 
(MM). Высокодозовая химиотерапия, за которой следует аутологическая трансплантация стволовых клеток, является 
стандартным подходом при лечении более молодых пациентов. Цель: изучить влияние введенных субпопуляций лимфоци­
тов на безрецидивную выживаемость (EFS) и общую выживаемость больных c ММ. Методы: методом проточной цито­
флуориметрии в периферической крови (PB) и продуктах афереза (АР) пациентов с ММ ( n = 41) изучали субпопуляции 
лимфоцитов и возможную корреляцию с исходом болезни. Результаты: субпопуляции лимфоцитов РB не влияли на EFS 
или OS. Остаточные клетки плазмы в АР не коррелировали с плохим прогнозом, в тоже время при высоком содержании 
В­клеток (CD19+) отмечали тенденцию к снижению EFS (P = 0,051). Высокое содержание CD4­клеток и увеличение 
соотношения CD4/CD8 были достоверно ассоциированы с повышением EFS. В отличие от этого, высокий процент HLA­
DR­положительных лимфоцитов имел отрицательное влияние на EFS и OS (P = 0,03 и 0,02 соответственно). Выводы: 
полученные данные позволяют предположить, что неактивированные (HLA­DR­отрицательные) хелперные CD4+ T­клетки 
в AP могут обладать антиопухолевыми  свойствами.
Ключевые слова: аутологический трансплантат, трансплантация стволовых клеток крови, корреляция, безрецидивная 
выживаемость, лимфоциты, множественная миелома.
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